To read the full story, subscribe or sign in.

Lepu’s MRG-003 cleared as China’s first EGFR ADC for advanced NPC

Nov. 4, 2025

Lepu Biopharma Co. Ltd. said Oct. 30 it won Chinese approval of a novel antibody-drug conjugate (ADC), Meiyouheng (becotatug vedotin injection), making it China’s first epidermal growth factor receptor (EGFR)-directed ADC for advanced nasopharyngeal cancer (NPC).

BioWorld BioWorld Asia Cancer Antibody-drug conjugate Asia-Pacific China NDA

Today's news in brief

BioWorld

BioWorld briefs for Nov. 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 17, 2025.

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld Science

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...

Illustration of magnifying glass inspecting brain

Anchoring, and bootstrapping, psychiatry into the precision medicine era

BioWorld

Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are...